In a major development for hereditary transthyretin-mediated amyloidosis (ATTRv-PN or hATTR-PN) patients, the US Food and Drug Administration (FDA) has approved Wainua (eplontersen), developed by AstraZeneca PLC and Ionis Pharmaceuticals Inc. This approval is particularly noteworthy as Wainua is the first and only FDA-approved medication for ATTRv-PN that can be self-administered using an auto-injector. The […]
China’s National Medical Products Administration (NMPA) has approved AstraZeneca’s Forxiga (dapagliflozin) for diminishing the risk of cardiovascular fatalities and hospitalizations in adults diagnosed with symptomatic chronic heart failure (HF). This follows an earlier authorization for patients suffering from heart failure with reduced ejection fraction (HFrEF). Now, Forxiga’s capabilities extend to all adults with symptomatic chronic […]
AstraZeneca has signed a deal valued at about $390 million with Atnahs Pharma, a portfolio company of Triton Fund V, to sell five of its hypertension drugs to the latter as they have lost patent protection across the world. The deal will give Atnahs Pharma the global commercial rights to the hypertension medicines – Inderal (propranolol), […]